According to Neurocrine Biosciences 's latest financial reports the company's total assets are $3.25 B. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2023-12-31 | $3.25 B | 37.27% |
2022-12-31 | $2.36 B | 14.29% |
2021-12-31 | $2.07 B | 19.47% |
2020-12-31 | $1.73 B | 32.83% |
2019-12-31 | $1.30 B | 31.5% |
2018-12-31 | $0.99 B | 21.47% |
2017-12-31 | $0.81 B | 123.94% |
2016-12-31 | $0.36 B | -23.1% |
2015-12-31 | $0.47 B | 95.36% |
2014-12-31 | $0.24 B | 57.12% |
2013-12-31 | $0.15 B | -21.08% |
2012-12-31 | $0.19 B | 41.64% |
2011-12-31 | $0.13 B | -4.19% |
2010-12-31 | $0.14 B | 103.94% |
2009-12-31 | $70.81 M | -40.08% |
2008-12-31 | $0.11 B | -57.28% |
2007-12-31 | $0.27 B | -29% |
2006-12-31 | $0.38 B | -19.34% |
2005-12-31 | $0.48 B | -6.95% |
2004-12-31 | $0.51 B | -6.44% |
2003-12-31 | $0.55 B | 108.21% |
2002-12-31 | $0.26 B | -23.04% |
2001-12-31 | $0.34 B |
Company | Total assets | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $226.50 B | 6,866.26% | ๐บ๐ธ USA |
AbbVie ABBV | $134.71 B | 4,043.17% | ๐บ๐ธ USA |
Eli Lilly LLY | $64.00 B | 1,868.58% | ๐บ๐ธ USA |
Repligen
RGEN | $2.82 B | -13.13% | ๐บ๐ธ USA |
Athersys ATHX | $7.42 M | -99.77% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $0.90 B | -72.18% | ๐บ๐ธ USA |
Palatin Technologies PTN | $13.55 M | -99.58% | ๐บ๐ธ USA |
Royalty Pharma RPRX | $16.38 B | 403.84% | ๐ฌ๐ง UK |